<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819156</url>
  </required_header>
  <id_info>
    <org_study_id>FE200486 CS12</org_study_id>
    <nct_id>NCT00819156</nct_id>
  </id_info>
  <brief_title>Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer</brief_title>
  <official_title>An Open-label, Randomised, Multi-centre, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Six Different Dosing Regimens in Patients With Prostate Cancer Treated for 12 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial was to evaluate the safety and efficacy of degarelix when comparing
      six different doses. The patients participating in the trial were treated with degarelix
      every month for a year. During the treatment the patients had to visit the clinic for
      investigations. Blood samples for testosterone, dihydrotestosterone, luteinizing hormone,
      follicle stimulating hormone, and Prostate Specific Antigen were taken and analysed
      throughout the trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Degarelix was not FDA regulated at the time of the trial. After completion of the trial
      degarelix has been approved by the FDA and is thus an FDA regulated intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Testosterone &lt;=0.5 Nanograms/Milliliter From Day 28 to Day 364</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients who achieved a testosterone level considered a castration level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Testosterone Level &lt;=0.5 Nanogram/Milliliter From Day 28 to Day 364 for Patients With Testosterone &lt;=0.5 Nanogram/Milliliter at Day 28</measure>
    <time_frame>Day 28 - 364</time_frame>
    <description>Number of patients who maintained a castration level of testosterone (&lt;=0.5 Nanogram/Milliliter) while on a maintenance dose of Degarelix from Day 28 - 364.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Testosterone &lt;=0.5 Nanogram/Milliliter at Day 28.</measure>
    <time_frame>Day 28</time_frame>
    <description>The number of patients who achieved the &lt;=0.5 nanogram/milliliter level for serum testosterone after the initial dose cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Testoterone &lt;=0.5 Nanogram/Milliliter at Day 3.</measure>
    <time_frame>Day 3</time_frame>
    <description>The number of patients who achieved the &lt;=0.5 nanogram/milliliter level for serum testosterone after 3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to 50 Percent Reduction in Prostate-Specific Antigen</measure>
    <time_frame>Day 0 (post dose) to Day 364</time_frame>
    <description>Median number of days after the first dose of Degarelix when the prostate-specific antigen levels fell to 50 percent of the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to 90 Percent Reduction in Prostate-Specific Antigen</measure>
    <time_frame>Day 0 (post dose) to Day 364</time_frame>
    <description>Median number of days after the first dose of Degarelix when the prostate-specific antigen levels fell to 90 percent of the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to Prostate-Specific Antigen Progression</measure>
    <time_frame>Day 0 (post dose) to Day 364</time_frame>
    <description>Median days to prostate-specific antigen increase of &gt;= 50 percent and &gt;=5 nanograms/milliliter compared to nadir on two consecutive visits at least two weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Serum Testosterone Levels</measure>
    <time_frame>Day 0 (Baseline), Days 1,3,7,14, and 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Prostate-specific Antigen Levels</measure>
    <time_frame>Day 0 (Baseline), Days 3, 7, 14, and 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Values of Di-Hydrotestosterone</measure>
    <time_frame>Day 0 (Baseline), Days 1, 3, 7, 14, and 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Values for Serum Luteinizing Hormone</measure>
    <time_frame>Day 0 (Baseline), Days 1, 3, 7, 14, and 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Values for Follicle Stimulation Hormone</measure>
    <time_frame>Day 0 (Baseline), Days 1, 3, 7, 14, and 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients With Abnormal Liver Function Tests</measure>
    <time_frame>364 days</time_frame>
    <description>The number of patients who had abnormal (defined as above upper limit of normal range(ULN)) alanine aminotransferase(ALT), aspartate aminotransferase levels, and bilirubin levels. Also includes the number of patients who had ALT increases &gt;3x ULN, and patients with ALT increases &gt;3x ULN with concurrent increases in bilirubin &gt;1.5 ULN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients With Markedly Abnormal Changes in Vital Signs or Body Weight</measure>
    <time_frame>Day 364</time_frame>
    <description>Vital sign and body weight values at the end of the trial are compared to baseline values. The table represents the number of patients in each group with normal baseline values and markedly abnormal end-of-study values.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Degarelix 200/80</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 200/120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 200/160</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 240/80</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 240/120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 240/160</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>degarelix</intervention_name>
    <description>Degarelix was given as subcutaneous injections.</description>
    <arm_group_label>Degarelix 200/80</arm_group_label>
    <arm_group_label>Degarelix 200/120</arm_group_label>
    <arm_group_label>Degarelix 200/160</arm_group_label>
    <arm_group_label>Degarelix 240/80</arm_group_label>
    <arm_group_label>Degarelix 240/120</arm_group_label>
    <arm_group_label>Degarelix 240/160</arm_group_label>
    <other_name>FE200486</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent prior to any study related procedures

          -  Proven prostate cancer in need for endocrine treatment, except for neoadjuvant
             hormonal therapy, but including patients with a rising PSA further to prostatectomy or
             radiotherapy

          -  ECOG score to be equal to or above 2

          -  Testosterone level within age-specific normal range

          -  PSA value equal to or above 2 ng/ml

          -  Life expectancy of at least 6 months

        Exclusion Criteria:

          -  Previous or current hormonal treatment of prostate cancer

          -  Recent or current treatment with any drugs modifying the testosterone level

          -  Candidate for curative treatment such as prostatectomy or radiotherapy

          -  History of severe asthma, anaphylactic reactions, angioedema, angioneurotic oedema or
             Quincke's Oedema

          -  Hypersensitivity towards any component of degarelix or mannitol

          -  Cancer disease within the last 5 years except for prostate cancer and some skin
             cancers

          -  Signs of liver impairment shown as elevated serum ALT or serum bilirubin

          -  Known hepatic disease

          -  Other laboratory abnormalities that judged by the investigator would interfere with
             the patients participation in the trial or the evaluation of the trial results

          -  Clinically significant disorder including excessive alcohol or drug abuse that may
             interfere with trial participation or influence the conclusion of the trial as judged
             by the investigator

          -  Mental incapacity or language barrier precluding adequate understanding or cooperation

          -  Having received an investigational product within the last 12 weeks preceding the
             trial

          -  Previous participation in this trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCL Saint Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum am Urban</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loretto Krankenhaus</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Euromed AG Klinik</name>
      <address>
        <city>Fürth</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Universitätsklinikum</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinszky Hospital, Urology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc Dél Pesti Hospital, Urology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pez Aladar County Hospital</name>
      <address>
        <city>Györ</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAZ County Hospital</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Local Gov. Szeged, Urology</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MÁV Hospital, Urology</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium MC</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalisttyczny</name>
      <address>
        <city>Siedlce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalisttyczny</name>
      <address>
        <city>Slupsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF2 Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Th Burghele Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sf. Ioan Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Botkin Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #1</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #29</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #50</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #60</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Urology of MoH</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Andros&quot; Urology Clinic</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #15</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #26</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy, Urology</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavlov Medical School Outpatient</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavlov medical School, Urology</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sct Petersburg State Medical Academy</name>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>370 Clarke Road</name>
      <address>
        <city>Glenwood, Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pretoria Urology Hospital</name>
      <address>
        <city>Hatfield, Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WITS Medical School</name>
      <address>
        <city>Parktown</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>401B Medical Centre</name>
      <address>
        <city>Pietermaritzburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunninghill Clinic</name>
      <address>
        <city>Sunninghill</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
  </location_countries>
  <results_reference>
    <citation>Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold Olesen T. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol. 2008 Oct;54(4):805-13. doi: 10.1016/j.eururo.2008.04.065. Epub 2008 May 8.</citation>
    <PMID>18538469</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2009</study_first_posted>
  <results_first_submitted>January 22, 2009</results_first_submitted>
  <results_first_submitted_qc>March 30, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 31, 2009</results_first_posted>
  <last_update_submitted>December 20, 2011</last_update_submitted>
  <last_update_submitted_qc>December 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two hundred and sixteen patients were screened. Twenty-seven were screening failures. Two randomized patients were not treated: one withdrew consent and the other had an elevated alanine aminotransferase value (an exclusion criteria found after randomization).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Degarelix 200/80</title>
          <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="P2">
          <title>Degarelix 200/120</title>
          <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="P3">
          <title>Degarelix 200/160</title>
          <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="P4">
          <title>Degarelix 240/80</title>
          <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="P5">
          <title>Degarelix 240/120</title>
          <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="P6">
          <title>Degarelix 240/160</title>
          <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomised and Treated (ITT Population)</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Testosterone &gt;1ng/ml from Day 28+</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Testosterone &gt;=.5ng/ml 2 visits</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prostate-specific antigen progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Degarelix 200/80</title>
          <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="B2">
          <title>Degarelix 200/120</title>
          <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Degarelix 200/160</title>
          <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="B4">
          <title>Degarelix 240/80</title>
          <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="B5">
          <title>Degarelix 240/120</title>
          <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="B6">
          <title>Degarelix 240/160</title>
          <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="33"/>
            <count group_id="B6" value="30"/>
            <count group_id="B7" value="187"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.9" spread="8.27"/>
                    <measurement group_id="B2" value="70.6" spread="7.72"/>
                    <measurement group_id="B3" value="73.3" spread="7.39"/>
                    <measurement group_id="B4" value="70.4" spread="7.07"/>
                    <measurement group_id="B5" value="70.7" spread="7.56"/>
                    <measurement group_id="B6" value="70.7" spread="8.59"/>
                    <measurement group_id="B7" value="70.9" spread="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Patients at Each Stage of Prostate Cancer</title>
          <description>Prostate cancer stage was classified to describe the extent of cancer. Localized refers to tumors without involvement of lymph nodes or metastasis. Advanced localized can be larger tummors that may involve the lymph nodes but no metastasis. Metastatic are more advanced cancers that are spreading beyond the original tumor.</description>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Localized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally advanced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not classifiable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Counts by Gleason Score</title>
          <description>The Gleason Score is a system of grading the aggressiveness of the prostate cancer and how fast it is likely to grow and spread. Scale is 2-10 with low numbers being the least aggressive and 10 being the most aggressive.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body mass index is a measure of body fat based on height and weight.</description>
          <units>kilograms per square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" spread="3.5" lower_limit="18.1" upper_limit="36"/>
                    <measurement group_id="B2" value="26.4" spread="3.74" lower_limit="20.3" upper_limit="36.8"/>
                    <measurement group_id="B3" value="25.9" spread="4.46" lower_limit="17.9" upper_limit="36.3"/>
                    <measurement group_id="B4" value="27.7" spread="5.3" lower_limit="18.5" upper_limit="41.1"/>
                    <measurement group_id="B5" value="26" spread="3.28" lower_limit="18.2" upper_limit="32.7"/>
                    <measurement group_id="B6" value="25.3" spread="2.73" lower_limit="20.3" upper_limit="29.8"/>
                    <measurement group_id="B7" value="26.3" spread="3.94" lower_limit="17.9" upper_limit="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Days Since Diagnosis of Prostate Cancer</title>
          <description>The mean number of days that have passed since a diagnosis of prostate cancer was made for each patient.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="493" spread="849"/>
                    <measurement group_id="B2" value="122" spread="230"/>
                    <measurement group_id="B3" value="375" spread="1098"/>
                    <measurement group_id="B4" value="383" spread="817"/>
                    <measurement group_id="B5" value="229" spread="508"/>
                    <measurement group_id="B6" value="352" spread="743"/>
                    <measurement group_id="B7" value="323" spread="756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median Serum Testosterone Level</title>
          <description>Testosterone is a steroid hormone from the androgen group, and the principal male sex hormone. This test measures the amount of testosterone in the blood. Androgen deprivation is used to manage prostate cancer.</description>
          <units>nanogram / milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.47" lower_limit="0.816" upper_limit="7.1"/>
                    <measurement group_id="B2" value="3.93" lower_limit="1.53" upper_limit="9.29"/>
                    <measurement group_id="B3" value="4.79" lower_limit="2.8" upper_limit="9.47"/>
                    <measurement group_id="B4" value="4.28" lower_limit="1.4" upper_limit="10.2"/>
                    <measurement group_id="B5" value="4.07" lower_limit="2.02" upper_limit="7.7"/>
                    <measurement group_id="B6" value="3.88" lower_limit="1.69" upper_limit="8.63"/>
                    <measurement group_id="B7" value="4.13" lower_limit="0.816" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Prostate-specific Antigen</title>
          <description>Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. High PSA levels have a positive correlation to prostate cancer.</description>
          <units>nanogram / milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.2" lower_limit="2.6" upper_limit="332"/>
                    <measurement group_id="B2" value="31.5" lower_limit="3.3" upper_limit="1730"/>
                    <measurement group_id="B3" value="31.5" lower_limit="2.6" upper_limit="901"/>
                    <measurement group_id="B4" value="23.1" lower_limit="3.6" upper_limit="586"/>
                    <measurement group_id="B5" value="35.3" lower_limit="2.4" upper_limit="1110"/>
                    <measurement group_id="B6" value="32" lower_limit="2" upper_limit="1297"/>
                    <measurement group_id="B7" value="27.6" lower_limit="2" upper_limit="1730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Testosterone &lt;=0.5 Nanograms/Milliliter From Day 28 to Day 364</title>
        <description>Number of patients who achieved a testosterone level considered a castration level.</description>
        <time_frame>12 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 200/80</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 200/120</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 200/160</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 240/80</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 240/120</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240/160</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Testosterone &lt;=0.5 Nanograms/Milliliter From Day 28 to Day 364</title>
          <description>Number of patients who achieved a testosterone level considered a castration level.</description>
          <population>ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="41" upper_limit="78"/>
                    <measurement group_id="O2" value="21" lower_limit="64" upper_limit="95"/>
                    <measurement group_id="O3" value="26" lower_limit="81" upper_limit="100"/>
                    <measurement group_id="O4" value="27" lower_limit="73" upper_limit="98"/>
                    <measurement group_id="O5" value="27" lower_limit="73" upper_limit="98"/>
                    <measurement group_id="O6" value="23" lower_limit="74" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>41</ci_lower_limit>
            <ci_upper_limit>78</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter from Day 28 to Day 364. The 95% Confidence Interval was calculated by the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>64</ci_lower_limit>
            <ci_upper_limit>95</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter from Day 28 to Day 364. The 95% Confidence Interval was calculated by the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>81</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter from Day 28 to Day 364. The 95% Confidence Interval was calculated by the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>73</ci_lower_limit>
            <ci_upper_limit>98</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter from Day 28 to Day 364. The 95% Confidence Interval was calculated by the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>73</ci_lower_limit>
            <ci_upper_limit>98</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter from Day 28 to Day 364. The 95% Confidence Interval was calculated by the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>92</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>74</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter from Day 28 to Day 364. The 95% Confidence Interval was calculated by the Clopper-Pearson method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Testosterone Level &lt;=0.5 Nanogram/Milliliter From Day 28 to Day 364 for Patients With Testosterone &lt;=0.5 Nanogram/Milliliter at Day 28</title>
        <description>Number of patients who maintained a castration level of testosterone (&lt;=0.5 Nanogram/Milliliter) while on a maintenance dose of Degarelix from Day 28 - 364.</description>
        <time_frame>Day 28 - 364</time_frame>
        <population>ITT population of patients with testoterone measurements &lt;=0.5 nanogram/milliliter at Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance Dose of 80 Milligram Per Cycle</title>
            <description>The two treatment groups that have a maintenance dose of 80 milligram per cycle in cycles 2-13 have been combined.</description>
          </group>
          <group group_id="O2">
            <title>Maintenance Dose of 120 Milligram Per Cycle</title>
            <description>The two treatment groups that have a maintenance dose of 120 milligram per cycle in cycles 2-13 have been combined.</description>
          </group>
          <group group_id="O3">
            <title>Maintenance Dose of 160 Milligram Per Cycle</title>
            <description>The two treatment groups that have a maintenance dose of 160 milligram per cycle in cycles 2-13 have been combined.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Testosterone Level &lt;=0.5 Nanogram/Milliliter From Day 28 to Day 364 for Patients With Testosterone &lt;=0.5 Nanogram/Milliliter at Day 28</title>
          <description>Number of patients who maintained a castration level of testosterone (&lt;=0.5 Nanogram/Milliliter) while on a maintenance dose of Degarelix from Day 28 - 364.</description>
          <population>ITT population of patients with testoterone measurements &lt;=0.5 nanogram/milliliter at Day 28.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="80" upper_limit="98"/>
                    <measurement group_id="O2" value="48" lower_limit="86" upper_limit="100"/>
                    <measurement group_id="O3" value="49" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>92</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>80</ci_lower_limit>
            <ci_upper_limit>98</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone (T) &lt;=0.5 nanograms (ng)/milliliter (mL) from Day 28 to Day 364 for Patients With T &lt;=0.5 ng/mL at Day 28. The 95% Confidence Interval was calculated by the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>86</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone (T) &lt;=0.5 nanograms (ng)/milliliter (mL) from Day 28 to Day 364 for Patients With T &lt;=0.5 ng/mL at Day 28. The 95% Confidence Interval was calculated by the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>93</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone (T) &lt;=0.5 nanograms (ng)/milliliter (mL) from Day 28 to Day 364 for Patients With T &lt;=0.5 ng/mL at Day 28. The 95% Confidence Interval was calculated by the Clopper-Pearson method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Testosterone &lt;=0.5 Nanogram/Milliliter at Day 28.</title>
        <description>The number of patients who achieved the &lt;=0.5 nanogram/milliliter level for serum testosterone after the initial dose cycle.</description>
        <time_frame>Day 28</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 200/80</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 200/120</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 200/160</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 240/80</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 240/120</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240/160</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Testosterone &lt;=0.5 Nanogram/Milliliter at Day 28.</title>
          <description>The number of patients who achieved the &lt;=0.5 nanogram/milliliter level for serum testosterone after the initial dose cycle.</description>
          <population>ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="51" upper_limit="85"/>
                    <measurement group_id="O2" value="29" lower_limit="75" upper_limit="98"/>
                    <measurement group_id="O3" value="31" lower_limit="84" upper_limit="100"/>
                    <measurement group_id="O4" value="29" lower_limit="83" upper_limit="100"/>
                    <measurement group_id="O5" value="31" lower_limit="80" upper_limit="99"/>
                    <measurement group_id="O6" value="27" lower_limit="77" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>70</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>51</ci_lower_limit>
            <ci_upper_limit>85</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter at Day 28. The 95% Confidence Interval was calculated with the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>75</ci_lower_limit>
            <ci_upper_limit>98</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter at Day 28. The 95% Confidence Interval was calculated with the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>84</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter at Day 28. The 95% Confidence Interval was calculated with the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>83</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter at Day 28. The 95% Confidence Interval was calculated with the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>80</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter at Day 28. The 95% Confidence Interval was calculated with the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>77</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter at Day 28. The 95% Confidence Interval was calculated with the Clopper-Pearson method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Testoterone &lt;=0.5 Nanogram/Milliliter at Day 3.</title>
        <description>The number of patients who achieved the &lt;=0.5 nanogram/milliliter level for serum testosterone after 3 days.</description>
        <time_frame>Day 3</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 200/80</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 200/120</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 200/160</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 240/80</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 240/120</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240/160</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Testoterone &lt;=0.5 Nanogram/Milliliter at Day 3.</title>
          <description>The number of patients who achieved the &lt;=0.5 nanogram/milliliter level for serum testosterone after 3 days.</description>
          <population>ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="65" upper_limit="94"/>
                    <measurement group_id="O2" value="30" lower_limit="79" upper_limit="99"/>
                    <measurement group_id="O3" value="27" lower_limit="70" upper_limit="96"/>
                    <measurement group_id="O4" value="28" lower_limit="78" upper_limit="99"/>
                    <measurement group_id="O5" value="30" lower_limit="76" upper_limit="98"/>
                    <measurement group_id="O6" value="28" lower_limit="78" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>83</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>65</ci_lower_limit>
            <ci_upper_limit>94</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter at Day 3. The 95% Confidence Interval was calculated with the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>79</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter at Day 3. The 95% Confidence Interval was calculated with the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>70</ci_lower_limit>
            <ci_upper_limit>96</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter at Day 3. The 95% Confidence Interval was calculated with the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>78</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter at Day 3. The 95% Confidence Interval was calculated with the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>76</ci_lower_limit>
            <ci_upper_limit>98</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter at Day 3. The 95% Confidence Interval was calculated with the Clopper-Pearson method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>78</ci_lower_limit>
            <ci_upper_limit>99</ci_upper_limit>
            <estimate_desc>The estimated value is the percentage of patients with Testosterone &lt;=0.5 nanograms/milliliter at Day 3. The 95% Confidence Interval was calculated with the Clopper-Pearson method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to 50 Percent Reduction in Prostate-Specific Antigen</title>
        <description>Median number of days after the first dose of Degarelix when the prostate-specific antigen levels fell to 50 percent of the baseline value.</description>
        <time_frame>Day 0 (post dose) to Day 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 200/80</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 200/120</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 200/160</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 240/80</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 240/120</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240/160</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Days to 50 Percent Reduction in Prostate-Specific Antigen</title>
          <description>Median number of days after the first dose of Degarelix when the prostate-specific antigen levels fell to 50 percent of the baseline value.</description>
          <population>ITT population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="7" upper_limit="224"/>
                    <measurement group_id="O2" value="14" lower_limit="3" upper_limit="84"/>
                    <measurement group_id="O3" value="14" lower_limit="3" upper_limit="42"/>
                    <measurement group_id="O4" value="14" lower_limit="3" upper_limit="56"/>
                    <measurement group_id="O5" value="14" lower_limit="3" upper_limit="84"/>
                    <measurement group_id="O6" value="14" lower_limit="3" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0933</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to 90 Percent Reduction in Prostate-Specific Antigen</title>
        <description>Median number of days after the first dose of Degarelix when the prostate-specific antigen levels fell to 90 percent of the baseline value.</description>
        <time_frame>Day 0 (post dose) to Day 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 200/80</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 200/120</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 200/160</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 240/80</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 240/120</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240/160</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Days to 90 Percent Reduction in Prostate-Specific Antigen</title>
          <description>Median number of days after the first dose of Degarelix when the prostate-specific antigen levels fell to 90 percent of the baseline value.</description>
          <population>ITT population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="28" upper_limit="168"/>
                    <measurement group_id="O2" value="56" lower_limit="14" upper_limit="336"/>
                    <measurement group_id="O3" value="56" lower_limit="14" upper_limit="336"/>
                    <measurement group_id="O4" value="56" lower_limit="14" upper_limit="196"/>
                    <measurement group_id="O5" value="56" lower_limit="28" upper_limit="364"/>
                    <measurement group_id="O6" value="56" lower_limit="14" upper_limit="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.165</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to Prostate-Specific Antigen Progression</title>
        <description>Median days to prostate-specific antigen increase of &gt;= 50 percent and &gt;=5 nanograms/milliliter compared to nadir on two consecutive visits at least two weeks apart.</description>
        <time_frame>Day 0 (post dose) to Day 364</time_frame>
        <population>Number of patients with PSA progression in the six groups n=0,3,1,4,4,2. Since no patients in the 200/80 group experience PSA progression the Days to progression could not be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 200/120</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 200/160</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 240/80</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 240/120</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 240/160</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Prostate-Specific Antigen Progression</title>
          <description>Median days to prostate-specific antigen increase of &gt;= 50 percent and &gt;=5 nanograms/milliliter compared to nadir on two consecutive visits at least two weeks apart.</description>
          <population>Number of patients with PSA progression in the six groups n=0,3,1,4,4,2. Since no patients in the 200/80 group experience PSA progression the Days to progression could not be calculated.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224" lower_limit="140" upper_limit="308"/>
                    <measurement group_id="O2" value="308" lower_limit="308" upper_limit="308"/>
                    <measurement group_id="O3" value="280" lower_limit="252" upper_limit="336"/>
                    <measurement group_id="O4" value="224" lower_limit="126" upper_limit="364"/>
                    <measurement group_id="O5" value="140" lower_limit="140" upper_limit="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.429</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Serum Testosterone Levels</title>
        <time_frame>Day 0 (Baseline), Days 1,3,7,14, and 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 200/80</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 200/120</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 200/160</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 240/80</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 240/120</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240/160</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Serum Testosterone Levels</title>
          <population>ITT population</population>
          <units>nanogram/milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" lower_limit="0.816" upper_limit="7.1"/>
                    <measurement group_id="O2" value="3.93" lower_limit="1.53" upper_limit="9.29"/>
                    <measurement group_id="O3" value="4.79" lower_limit="2.8" upper_limit="9.47"/>
                    <measurement group_id="O4" value="4.28" lower_limit="1.4" upper_limit="10.2"/>
                    <measurement group_id="O5" value="4.07" lower_limit="2.02" upper_limit="7.7"/>
                    <measurement group_id="O6" value="3.88" lower_limit="1.69" upper_limit="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (n=30,32,32,30,33,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.654" lower_limit="0.167" upper_limit="1.81"/>
                    <measurement group_id="O2" value="0.436" lower_limit="0.207" upper_limit="1.21"/>
                    <measurement group_id="O3" value="0.465" lower_limit="0.287" upper_limit="2.44"/>
                    <measurement group_id="O4" value="0.563" lower_limit="0.2" upper_limit="3"/>
                    <measurement group_id="O5" value="0.453" lower_limit="0.21" upper_limit="3.32"/>
                    <measurement group_id="O6" value="0.576" lower_limit="0.261" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=30,32,31,30,33,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.308" lower_limit="0.121" upper_limit="2.81"/>
                    <measurement group_id="O2" value="0.26" lower_limit="0.139" upper_limit="0.657"/>
                    <measurement group_id="O3" value="0.281" lower_limit="0.125" upper_limit="0.64"/>
                    <measurement group_id="O4" value="0.265" lower_limit="0.119" upper_limit="0.586"/>
                    <measurement group_id="O5" value="0.268" lower_limit="0.133" upper_limit="0.912"/>
                    <measurement group_id="O6" value="0.261" lower_limit="0.144" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=30,32,32,30,33,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.283" lower_limit="0.098" upper_limit="4"/>
                    <measurement group_id="O2" value="0.237" lower_limit="0.066" upper_limit="1.43"/>
                    <measurement group_id="O3" value="0.198" lower_limit="0.087" upper_limit="0.808"/>
                    <measurement group_id="O4" value="0.193" lower_limit="0.104" upper_limit="0.549"/>
                    <measurement group_id="O5" value="0.216" lower_limit="0.116" upper_limit="1.55"/>
                    <measurement group_id="O6" value="0.207" lower_limit="0.074" upper_limit="4.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=30,32,32,30,33,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.173" lower_limit="0.025" upper_limit="4.77"/>
                    <measurement group_id="O2" value="0.144" lower_limit="0.054" upper_limit="1.62"/>
                    <measurement group_id="O3" value="0.122" lower_limit="0.025" upper_limit="0.617"/>
                    <measurement group_id="O4" value="0.152" lower_limit="0.025" upper_limit="0.641"/>
                    <measurement group_id="O5" value="0.134" lower_limit="0.05" upper_limit="0.924"/>
                    <measurement group_id="O6" value="0.126" lower_limit="0.055" upper_limit="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364 (n=20,23,26,28,27,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.137" lower_limit="0.025" upper_limit="1.31"/>
                    <measurement group_id="O2" value="0.124" lower_limit="0.025" upper_limit="0.53"/>
                    <measurement group_id="O3" value="0.105" lower_limit="0.025" upper_limit="0.221"/>
                    <measurement group_id="O4" value="0.126" lower_limit="0.025" upper_limit="1.31"/>
                    <measurement group_id="O5" value="0.12" lower_limit="0.025" upper_limit="0.287"/>
                    <measurement group_id="O6" value="0.124" lower_limit="0.05" upper_limit="0.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Prostate-specific Antigen Levels</title>
        <time_frame>Day 0 (Baseline), Days 3, 7, 14, and 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 200/80</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 200/120</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 200/160</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 240/80</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 240/120</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240/160</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Prostate-specific Antigen Levels</title>
          <population>ITT population</population>
          <units>nanogram / milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="2.6" upper_limit="332"/>
                    <measurement group_id="O2" value="31.5" lower_limit="3.3" upper_limit="1730"/>
                    <measurement group_id="O3" value="31.5" lower_limit="2.6" upper_limit="901"/>
                    <measurement group_id="O4" value="23.1" lower_limit="3.6" upper_limit="586"/>
                    <measurement group_id="O5" value="35.3" lower_limit="2.4" upper_limit="1110"/>
                    <measurement group_id="O6" value="32" lower_limit="2" upper_limit="1297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=29,30,28,29,33,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="2.4" upper_limit="207"/>
                    <measurement group_id="O2" value="29.9" lower_limit="3" upper_limit="1061"/>
                    <measurement group_id="O3" value="27.8" lower_limit="2" upper_limit="443"/>
                    <measurement group_id="O4" value="22.2" lower_limit="2.7" upper_limit="503"/>
                    <measurement group_id="O5" value="26.3" lower_limit="1.8" upper_limit="928"/>
                    <measurement group_id="O6" value="25.2" lower_limit="1.3" upper_limit="945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=30,32,32,30,33,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="1.9" upper_limit="138"/>
                    <measurement group_id="O2" value="18.5" lower_limit="2.4" upper_limit="420"/>
                    <measurement group_id="O3" value="16.5" lower_limit="1.8" upper_limit="234"/>
                    <measurement group_id="O4" value="14.8" lower_limit="2.4" upper_limit="339"/>
                    <measurement group_id="O5" value="20.8" lower_limit="1.5" upper_limit="611"/>
                    <measurement group_id="O6" value="16.9" lower_limit="0.9" upper_limit="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=29,31,32,29,33,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="1" upper_limit="69.5"/>
                    <measurement group_id="O2" value="10.9" lower_limit="1.8" upper_limit="155"/>
                    <measurement group_id="O3" value="9.9" lower_limit="1.3" upper_limit="142"/>
                    <measurement group_id="O4" value="7.1" lower_limit="1.4" upper_limit="213"/>
                    <measurement group_id="O5" value="13.4" lower_limit="0.4" upper_limit="490"/>
                    <measurement group_id="O6" value="8.35" lower_limit="0.4" upper_limit="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364 (n=20,23,26,28,27,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="0.1" upper_limit="5.5"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.1" upper_limit="21.2"/>
                    <measurement group_id="O3" value="0.95" lower_limit="0.1" upper_limit="21.6"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.1" upper_limit="135"/>
                    <measurement group_id="O5" value="0.8" lower_limit="0.1" upper_limit="48.6"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.1" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Values of Di-Hydrotestosterone</title>
        <time_frame>Day 0 (Baseline), Days 1, 3, 7, 14, and 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 200/80</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 200/120</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 200/160</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 240/80</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 240/120</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240/160</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Values of Di-Hydrotestosterone</title>
          <population>ITT population</population>
          <units>picogram / milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (Baseline; n=25,30,26,23,23,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430" lower_limit="140" upper_limit="2600"/>
                    <measurement group_id="O2" value="330" lower_limit="94" upper_limit="760"/>
                    <measurement group_id="O3" value="310" lower_limit="170" upper_limit="630"/>
                    <measurement group_id="O4" value="330" lower_limit="20" upper_limit="760"/>
                    <measurement group_id="O5" value="350" lower_limit="160" upper_limit="640"/>
                    <measurement group_id="O6" value="290" lower_limit="160" upper_limit="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (n=23,27,25,24,26,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" lower_limit="41" upper_limit="320"/>
                    <measurement group_id="O2" value="95" lower_limit="54" upper_limit="290"/>
                    <measurement group_id="O3" value="110" lower_limit="44" upper_limit="250"/>
                    <measurement group_id="O4" value="130" lower_limit="30" upper_limit="380"/>
                    <measurement group_id="O5" value="110" lower_limit="60" upper_limit="480"/>
                    <measurement group_id="O6" value="115" lower_limit="49" upper_limit="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=23,27,25,25,27,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="22" upper_limit="150"/>
                    <measurement group_id="O2" value="67" lower_limit="32" upper_limit="130"/>
                    <measurement group_id="O3" value="70" lower_limit="22" upper_limit="130"/>
                    <measurement group_id="O4" value="66" lower_limit="25" upper_limit="180"/>
                    <measurement group_id="O5" value="73" lower_limit="10" upper_limit="190"/>
                    <measurement group_id="O6" value="67" lower_limit="10" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=26,30,24,26,30,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="10" upper_limit="260"/>
                    <measurement group_id="O2" value="65" lower_limit="31" upper_limit="220"/>
                    <measurement group_id="O3" value="61.5" lower_limit="22" upper_limit="150"/>
                    <measurement group_id="O4" value="56.5" lower_limit="21" upper_limit="130"/>
                    <measurement group_id="O5" value="61" lower_limit="20" upper_limit="240"/>
                    <measurement group_id="O6" value="77.5" lower_limit="20" upper_limit="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=19,27,25,23,25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="10" upper_limit="440"/>
                    <measurement group_id="O2" value="51" lower_limit="22" upper_limit="120"/>
                    <measurement group_id="O3" value="42" lower_limit="10" upper_limit="110"/>
                    <measurement group_id="O4" value="57" lower_limit="10" upper_limit="110"/>
                    <measurement group_id="O5" value="59" lower_limit="10" upper_limit="130"/>
                    <measurement group_id="O6" value="53" lower_limit="32" upper_limit="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364 (n=17,21,20,25,25,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="10" upper_limit="79"/>
                    <measurement group_id="O2" value="39" lower_limit="10" upper_limit="73"/>
                    <measurement group_id="O3" value="34" lower_limit="10" upper_limit="72"/>
                    <measurement group_id="O4" value="40" lower_limit="10" upper_limit="120"/>
                    <measurement group_id="O5" value="39" lower_limit="10" upper_limit="210"/>
                    <measurement group_id="O6" value="40" lower_limit="10" upper_limit="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Values for Serum Luteinizing Hormone</title>
        <time_frame>Day 0 (Baseline), Days 1, 3, 7, 14, and 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 200/80</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 200/120</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 200/160</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 240/80</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 240/120</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240/160</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Values for Serum Luteinizing Hormone</title>
          <population>ITT population</population>
          <units>international units / liter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.5" upper_limit="9.6"/>
                    <measurement group_id="O2" value="4" lower_limit="1.6" upper_limit="15"/>
                    <measurement group_id="O3" value="5.05" lower_limit="1.2" upper_limit="27.6"/>
                    <measurement group_id="O4" value="5.6" lower_limit="1" upper_limit="18"/>
                    <measurement group_id="O5" value="3.9" lower_limit="1.6" upper_limit="25.9"/>
                    <measurement group_id="O6" value="6" lower_limit="1.6" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (n=28,30,32,28,31,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.05" upper_limit="5.7"/>
                    <measurement group_id="O2" value="0.65" lower_limit="0.3" upper_limit="3.4"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.2" upper_limit="4.6"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.2" upper_limit="5.8"/>
                    <measurement group_id="O5" value="0.7" lower_limit="0.3" upper_limit="7.2"/>
                    <measurement group_id="O6" value="0.75" lower_limit="0.4" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=29,30,28,29,33,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.1" upper_limit="2.7"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.2" upper_limit="1.9"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.2" upper_limit="2.1"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.2" upper_limit="1.3"/>
                    <measurement group_id="O5" value="0.4" lower_limit="0.2" upper_limit="2.4"/>
                    <measurement group_id="O6" value="0.55" lower_limit="0.2" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=30,32,32,30,33,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.05" upper_limit="5.7"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.2" upper_limit="2.5"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.2" upper_limit="3.4"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.05" upper_limit="3.4"/>
                    <measurement group_id="O5" value="0.5" lower_limit="0.2" upper_limit="2.5"/>
                    <measurement group_id="O6" value="0.75" lower_limit="0.2" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=29,31,32,29,33,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.05" upper_limit="7.4"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.1" upper_limit="2.8"/>
                    <measurement group_id="O3" value="0.35" lower_limit="0.05" upper_limit="4.5"/>
                    <measurement group_id="O4" value="0.3" lower_limit="0.05" upper_limit="5.1"/>
                    <measurement group_id="O5" value="0.3" lower_limit="0.05" upper_limit="1.8"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.05" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364 (n=20,23,26,28,27,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.05" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.05" upper_limit="2.3"/>
                    <measurement group_id="O3" value="0.2" lower_limit="0.05" upper_limit="0.6"/>
                    <measurement group_id="O4" value="0.4" lower_limit="0.05" upper_limit="2.5"/>
                    <measurement group_id="O5" value="0.2" lower_limit="0.05" upper_limit="0.8"/>
                    <measurement group_id="O6" value="0.3" lower_limit="0.05" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Values for Follicle Stimulation Hormone</title>
        <time_frame>Day 0 (Baseline), Days 1, 3, 7, 14, and 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 200/80</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 200/120</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 200/160</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 240/80</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 240/120</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240/160</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Values for Follicle Stimulation Hormone</title>
          <population>ITT population</population>
          <units>international units / liter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.35" lower_limit="2.3" upper_limit="45.4"/>
                    <measurement group_id="O2" value="9.25" lower_limit="2.4" upper_limit="39.2"/>
                    <measurement group_id="O3" value="9" lower_limit="3.8" upper_limit="40.7"/>
                    <measurement group_id="O4" value="9.7" lower_limit="4.1" upper_limit="61.7"/>
                    <measurement group_id="O5" value="7" lower_limit="2.3" upper_limit="76.1"/>
                    <measurement group_id="O6" value="10.2" lower_limit="1.8" upper_limit="67.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (n=28,30,32,28,31,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.15" lower_limit="1.4" upper_limit="28.6"/>
                    <measurement group_id="O2" value="5.65" lower_limit="1.5" upper_limit="24.8"/>
                    <measurement group_id="O3" value="5.35" lower_limit="2.3" upper_limit="24.8"/>
                    <measurement group_id="O4" value="6.2" lower_limit="2.4" upper_limit="46.2"/>
                    <measurement group_id="O5" value="4.4" lower_limit="1.7" upper_limit="55.2"/>
                    <measurement group_id="O6" value="5.9" lower_limit="1" upper_limit="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=29,30,28,29,33,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="0.8" upper_limit="14.4"/>
                    <measurement group_id="O2" value="3.15" lower_limit="1" upper_limit="14.1"/>
                    <measurement group_id="O3" value="3.25" lower_limit="1.2" upper_limit="13.5"/>
                    <measurement group_id="O4" value="3.3" lower_limit="1.4" upper_limit="9.3"/>
                    <measurement group_id="O5" value="2.5" lower_limit="0.9" upper_limit="31.5"/>
                    <measurement group_id="O6" value="3.1" lower_limit="0.7" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (n=30,32,32,30,33,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.3" upper_limit="9.3"/>
                    <measurement group_id="O2" value="1.95" lower_limit="0.6" upper_limit="12.9"/>
                    <measurement group_id="O3" value="1.85" lower_limit="0.8" upper_limit="8.7"/>
                    <measurement group_id="O4" value="1.85" lower_limit="0.7" upper_limit="16"/>
                    <measurement group_id="O5" value="1.4" lower_limit="0.5" upper_limit="16.1"/>
                    <measurement group_id="O6" value="2.55" lower_limit="0.6" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=29,31,32,29,33,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.05" upper_limit="11.5"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.3" upper_limit="11.2"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.2" upper_limit="7.9"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.2" upper_limit="8.5"/>
                    <measurement group_id="O5" value="0.7" lower_limit="0.1" upper_limit="8"/>
                    <measurement group_id="O6" value="0.95" lower_limit="0.2" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364 (n=20,23,26,28,27,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.2" upper_limit="7"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.2" upper_limit="7.6"/>
                    <measurement group_id="O3" value="1.45" lower_limit="0.2" upper_limit="6.4"/>
                    <measurement group_id="O4" value="1.75" lower_limit="0.1" upper_limit="13"/>
                    <measurement group_id="O5" value="1.1" lower_limit="0.3" upper_limit="5.3"/>
                    <measurement group_id="O6" value="2.2" lower_limit="0.3" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients With Abnormal Liver Function Tests</title>
        <description>The number of patients who had abnormal (defined as above upper limit of normal range(ULN)) alanine aminotransferase(ALT), aspartate aminotransferase levels, and bilirubin levels. Also includes the number of patients who had ALT increases &gt;3x ULN, and patients with ALT increases &gt;3x ULN with concurrent increases in bilirubin &gt;1.5 ULN.</description>
        <time_frame>364 days</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 200/80</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 200/120</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 200/160</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 240/80</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 240/120</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240/160</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients With Abnormal Liver Function Tests</title>
          <description>The number of patients who had abnormal (defined as above upper limit of normal range(ULN)) alanine aminotransferase(ALT), aspartate aminotransferase levels, and bilirubin levels. Also includes the number of patients who had ALT increases &gt;3x ULN, and patients with ALT increases &gt;3x ULN with concurrent increases in bilirubin &gt;1.5 ULN.</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal alanine aminotransferase (ALT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal aspartate aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt;3x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT&gt;3x ULN and bilirubin &gt;1.5x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients With Markedly Abnormal Changes in Vital Signs or Body Weight</title>
        <description>Vital sign and body weight values at the end of the trial are compared to baseline values. The table represents the number of patients in each group with normal baseline values and markedly abnormal end-of-study values.</description>
        <time_frame>Day 364</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 200/80</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 200/120</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 200/160</title>
            <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 240/80</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 240/120</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240/160</title>
            <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients With Markedly Abnormal Changes in Vital Signs or Body Weight</title>
          <description>Vital sign and body weight values at the end of the trial are compared to baseline values. The table represents the number of patients in each group with normal baseline values and markedly abnormal end-of-study values.</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diastolic blood pressure &lt;=50 and decrease &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure &gt;=105 and increase &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse &lt;=50 and decrease &gt;=15 from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse &gt;=120 and increase of &gt;=15 from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure &lt;=90 and decrease &gt;=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure &gt;=180 and increase &gt;=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight decrease of &gt;=7% from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight increase of &gt;=7% from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Degarelix 200/80</title>
          <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="E2">
          <title>Degarelix 200/120</title>
          <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="E3">
          <title>Degarelix 200/160</title>
          <description>Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="E4">
          <title>Degarelix 240/80</title>
          <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="E5">
          <title>Degarelix 240/120</title>
          <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
        <group group_id="E6">
          <title>Degarelix 240/160</title>
          <description>Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintainance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3"/>
                <counts group_id="E2" subjects_affected="6"/>
                <counts group_id="E3" subjects_affected="4"/>
                <counts group_id="E4" subjects_affected="4"/>
                <counts group_id="E5" subjects_affected="6"/>
                <counts group_id="E6" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Intervertebral disc compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Acoustic neuroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Metastases to penis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 7.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17"/>
                <counts group_id="E2" subjects_affected="21"/>
                <counts group_id="E3" subjects_affected="24"/>
                <counts group_id="E4" subjects_affected="19"/>
                <counts group_id="E5" subjects_affected="23"/>
                <counts group_id="E6" subjects_affected="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" events="17" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="11" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="5" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Testicular atrophy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E4" events="14" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

